hotspot -WSS

hotspot

author：knowledge 2025-10-02 19:21:09 - browse：8

Electrocardiogram in the shape of the United States map — Adobe

The market for artificial intelligence in health care is about as transparent as a brick wall. New tools achieve impressive results in published studies. But it is often difficult to compare them head to head with similar products, or tell whether they will work on different kinds of patients.

A new company is promising to change that — if it can convince AI developers to expose their products to more rigorous testing.

Called Dandelion Health, the New York-based firm is launching a first-of-its-kind public service to evaluate AI products on independent data designed to root out weaknesses and reveal bias. The company said Wednesday its initial pilot program, to begin next month, will focus on testing algorithms that use electrocardiograms to predict heart conditions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Free Covid tests will again be offered to all U.S. households

WSS

Midwives could help bridge maternal health disparities in the U.S.

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Why palliative psychiatry is worth discussing

Fed up with FDA, ALS advocates consider a take

'A game

Eli Lilly CEO gives to Mike Pence presidential super PAC

knowledge

hotspot

entertainment

United colonoscopy coverage change 'may cost lives,' doctors say

Antivenom research: Lessons from HIV applied in search for universal antidote

BioMarin wins approval for gene therapy to treat hemophilia A

PBMs drew scrutiny in House hearing — and so did pharma

Jerome Adams on the need for new antivirals for Covid

House panel takes first step toward fixing drug shortages

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Ed Silverman on new gene therapies, biosimilars, coffee, and more

FDA approval of Sarepta Duchenne genetic therapy gives me hope

New documents shed light on MD Anderson Cancer Institute feud

entertainment

Patients, doctors press FTC to beef up hospital merger scrutiny

Medicare to pay more for cardiac rehab in hospital outpatient clinics

PBMs drew scrutiny in House hearing — and so did pharma

Chamber of Commerce, DOJ clash in court over drug prices

Medicare inequities exacerbate Puerto Rico’s health disparities

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

entertainment

entertainment

entertainment

focus